Log in to your Inderes Free account to see all free content on this page.
Guard Therapeutics
1.30 SEK
-0.38 %
Less than 1K followers
GUARD
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.38 %
0.00 %
-94.42 %
-92.31 %
-93.00 %
-92.82 %
-97.00 %
-97.80 %
-99.92 %
Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.
Read moreMarket cap
26.12M SEK
Turnover
192.72K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.2.
2026
Annual report '25
All
Webcasts
Press releases
ShowingAll content types
Guard Therapeutics appoints Redeye as financial advisor in the strategic review
Guard Therapeutics changes Certified Adviser to Redeye AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio